U.S. market Closed. Opens in 1 day 33 minutes

TCRX | TScan Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue21.05M13.54M10.14M1.08MN/A
Cost of Revenue5.36M5.14M3.33M20.58M519.00K
Gross Profit15.69M8.40M6.81M-19.49M-519.00K
Operating Expenses109.15M80.17M58.78M27.32M14.21M
Selling, General & Admin20.99M20.35M13.83M6.74M4.77M
Research & Development88.15M59.82M44.95M20.58M9.44M
Other Operating Expenses-88.15M1.59M16.00KN/AN/A
Operating Income-93.46M-66.64M-48.64M-26.23M-14.21M
Other Expenses / Income4.24M415.00K16.00K106.00K552.00K
Before Tax Income-89.22M-66.22M-48.62M-26.13M-13.66M
Income Tax Expenses5.19M-415.00K3.09M-106.00K-552.00K
Net Income-89.22M-65.81M-48.62M-26.02M-13.11M
Interest Expenses3.76M1.18MN/AN/AN/A
Basic Shares Outstanding65.60M24.05M23.91M24.94M24.94M
Diluted Shares Outstanding65.60M24.05M23.91M24.94M24.94M
EBITDA-88.10M-65.05M-45.31M-25.00M-13.69M
EBITDA Margin-418.53%-480.57%-446.83%-2,304.42%0.00%
EBIT-80.27M-65.05M-45.53M-26.13M-13.66M
EBIT Margin-381.33%-480.57%-449.00%-2,408.02%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙